CR20230180A - Inhibidores de interleucina-17 - Google Patents

Inhibidores de interleucina-17

Info

Publication number
CR20230180A
CR20230180A CR20230180A CR20230180A CR20230180A CR 20230180 A CR20230180 A CR 20230180A CR 20230180 A CR20230180 A CR 20230180A CR 20230180 A CR20230180 A CR 20230180A CR 20230180 A CR20230180 A CR 20230180A
Authority
CR
Costa Rica
Prior art keywords
interleukin
inhibitors
formamido
pyridyl
diseases
Prior art date
Application number
CR20230180A
Other languages
English (en)
Inventor
Klaus Weigand
Thomas Josef Troxler
Pascal Furet
Achim Schlapbach
David Orain
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20230180A publication Critical patent/CR20230180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de 2-formamido (<em>N</em>-fenil y <em>N</em>-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17
CR20230180A 2020-11-02 2021-11-01 Inhibidores de interleucina-17 CR20230180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20205121 2020-11-02
PCT/IB2021/060092 WO2022091056A1 (en) 2020-11-02 2021-11-01 Interleukin-17 inhibitors

Publications (1)

Publication Number Publication Date
CR20230180A true CR20230180A (es) 2023-05-25

Family

ID=73059405

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230180A CR20230180A (es) 2020-11-02 2021-11-01 Inhibidores de interleucina-17

Country Status (19)

Country Link
US (1) US20230391782A1 (es)
EP (1) EP4237417A1 (es)
JP (1) JP2023547470A (es)
KR (1) KR20230091945A (es)
CN (1) CN116323596A (es)
AR (1) AR123962A1 (es)
AU (1) AU2021368247B2 (es)
CA (1) CA3190738A1 (es)
CL (1) CL2023001220A1 (es)
CO (1) CO2023005280A2 (es)
CR (1) CR20230180A (es)
DO (1) DOP2023000081A (es)
EC (1) ECSP23030375A (es)
IL (1) IL302447A (es)
MX (1) MX2023005076A (es)
PE (1) PE20231047A1 (es)
TW (1) TW202227408A (es)
UY (1) UY39484A (es)
WO (1) WO2022091056A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
WO2024115662A1 (en) 2022-12-02 2024-06-06 Leo Pharma A/S Small molecule modulators of il-17

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US20050070567A1 (en) 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
ES2533074T3 (es) 2010-04-26 2015-04-07 Novartis Ag Medio de cultivo celular mejorado
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
JP6196678B2 (ja) 2012-10-24 2017-09-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
UY35315A (es) 2013-02-08 2014-09-30 Novartis Ag Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
SG10202100916PA (en) 2015-02-02 2021-02-25 Valo Early Discovery Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
CA3121719A1 (en) 2018-12-19 2020-06-25 Leo Pharma A/S Amino-acid anilides as small molecule modulators of il-17

Also Published As

Publication number Publication date
JP2023547470A (ja) 2023-11-10
CN116323596A (zh) 2023-06-23
DOP2023000081A (es) 2023-06-15
AU2021368247A1 (en) 2023-05-18
IL302447A (en) 2023-06-01
US20230391782A1 (en) 2023-12-07
AU2021368247A9 (en) 2023-10-05
UY39484A (es) 2022-06-30
EP4237417A1 (en) 2023-09-06
AR123962A1 (es) 2023-01-25
AU2021368247B2 (en) 2023-10-05
KR20230091945A (ko) 2023-06-23
WO2022091056A1 (en) 2022-05-05
MX2023005076A (es) 2023-05-16
CA3190738A1 (en) 2022-05-05
CO2023005280A2 (es) 2023-05-19
ECSP23030375A (es) 2023-05-31
CL2023001220A1 (es) 2023-12-22
PE20231047A1 (es) 2023-07-11
TW202227408A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
CR20230180A (es) Inhibidores de interleucina-17
CR20210552A (es) Inhibidores del inflamasoma nlrp3
CR20210045A (es) Inhibidores de inflamasoma nlrp3
CR20220031A (es) Inhibidores tricíclicos de kars dependientes de akr1c3
MA42376A (fr) Dérivés d&#39;oxopyridine substitués
PH12020550341A1 (en) Niraparib formulations
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MA37742B1 (fr) Dérivés d&#39;oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
CR20210216A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2023011624A (es) Anticuerpos anti-il-2r agonistas y metodos de uso.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2021004860A (es) Piridazinas novedosas.
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
WO2017168454A3 (en) Novel compounds as btk inhibitors
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
ZA202210027B (en) Compositions of vitamin a palmitate, processes for their preparation, uses and methods comprising them